Parkinson´s and Alzheimer´s Diseases and Natural Products: Pathologies and Medication of the New Times-Reference-Cited by-同舟云学术

Parkinson´s and Alzheimer´s Diseases and Natural Products: Pathologies and Medication of the New Times

Published:2020-12-31 Issue:2 Volume:19 Page:112-113
ISSN:1570-159X
Container-title:Current Neuropharmacology
language:en
Short-container-title:CN

Author:

Nabavi Seyed Mohammad¹,Sobarzo-Sánchez Eduardo²

Affiliation:

1. Applied Biotechnology Research Center Baqiyatallah University of Medical Sciences Tehran, Sheikh Bahaei St., 19945-546, Iran

2. Grupo de Investigación en Química Médica y Bio-inorgánica (QMEDBIN) Facultad de Ciencias de la Salud Universidad Central de Chile Lord Cochrane 417, Santiago, Spain

Publisher

Bentham Science Publishers Ltd.

Subject

Pharmacology (medical),Psychiatry and Mental health,Neurology (clinical),Neurology,Pharmacology,General Medicine

Reference5 articles.

1. Steffen J.K.; Reker P.; Mennicken F.K.; Dembek T.A.; Dafsari H.S.; Fink G.R.; Barbe M.T.; Fink G.R.; Visser-Vandewalle V.; Bipolar directional deep brain stimulation in essential and parkinsonian tremor. Neuromodulation 2020,23,543-549

2. Singleton W.G.B.; Ashida, Reiko.; Patel, N. K. Deep brain stimulation for facial pain. Prog Neurol Surg 2020,35,141-161

3. Yang X.; Chen Q.; Efficacy of the combined use of donepezil with either quetiapine or sodium valproate in patients with Alzheimer’s disease with behavioral and psychological symptoms of dementia, and their effects on vascular endothelial growth factors. Exp Ther Med 2021,21,10

4. Wada-Isoe K.; Kikuchi T.; Umeda-Kameyama Y.; Akishita M.; Mori T.; Nakamura Y.; ABC dementia scale classifies alzheimer’s disease patients into subgroups characterized by activities of daily living, behavioral and psychological symptoms of dementia, and cognitive function. J Alzheimers Dis 2020,73,383-392

5. Lu X.; Chen J.; Shu H.; Wang Z.; Shi Y.; Yuan Y.; Xie C.; Liao W.; Su F.; Shi Y.; Zhang Z.; Predicting conversion to Alzheimer’s disease among individual high-risk patients using the characterizing AD risk events index model. CNS Neurosci Ther 2020,26,720-726

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimization, Characterization and In-Vitro Cellular Uptake of Donepezil-Loaded NanoCrystVesicles;Journal of Cluster Science;2024-04-06

2. Neuroprotective effects of tanshinone IIA in experimental model of Parkinson disease in rats;Arabian Journal of Chemistry;2022-11

3. Recent trends of natural based therapeutics for mitochondria targeting in Alzheimer’s disease;Mitochondrion;2022-05